Full Breakdown
NHS England Pauses New Hormone Treatment Referrals for Minors
3/9/2026, 4:49:15 AM
Overview of the Decision
NHS England has announced a pause on new referrals for masculinising or feminising hormone treatments for 16 and 17-year-olds, following a comprehensive review that deemed the existing evidence insufficient to support the continued use of these treatments. This decision comes after the Cass review, which recommended extreme caution in administering such treatments to minors.
Findings of the Review
The review conducted by NHS England found that the available clinical evidence regarding the benefits and harms of hormone treatments for young people with gender dysphoria was "really weak." Professor James Palmer, National Medical Director for Specialised Services at NHS England, stated that the review established a lack of conclusive evidence to support the use of these hormones for individuals under 18. As a result, NHS England has initiated a 90-day public consultation to gather further insights before finalizing its policy on the matter.
Current Treatment Protocols
While new referrals for hormone treatments are paused, existing patients aged under 18 who are currently receiving cross-sex hormones will continue their treatment, subject to individual clinical reviews. NHS England emphasized that alternative support options, including mental health services and referrals to specialized gender clinics, remain available for young individuals experiencing gender incongruence.
Responses from Advocacy Groups
The decision has sparked significant reactions from advocacy groups. Tammy Hymas, policy lead at TransActual, criticized the pause as a "profound attack on young people’s bodily autonomy," suggesting that it disproportionately targets transgender individuals. Conversely, Helen Joyce from Sex Matters expressed that the pause was overdue, arguing that minors are too young to consent to irreversible medical treatments.
TransLucent, another advocacy group, labeled the move as "yet another blatant act of discrimination against transgender youths' healthcare," indicating potential legal action in response to the decision. They plan to critically assess NHS England's evidence before proceeding.
Broader Context and Implications
The decision to pause new hormone treatment referrals follows a series of controversies surrounding the prescription of cross-sex hormones to minors. A legal case led by Keira Bell, who regretted her hormone treatment as a teenager, highlighted the complexities and risks associated with such medical interventions. Although her case was dismissed in May 2025, it prompted discussions about the safety and appropriateness of hormone treatments for young people.
The Department of Health and Social Care reiterated that the safety and wellbeing of children and young people are paramount, asserting that NHS England's decisions are guided by expert scientific and clinical advice.
What's Next
The 90-day consultation period will allow NHS England to gather feedback from healthcare professionals and advocacy groups, aiming to ensure that no critical evidence has been overlooked. A final policy decision regarding the use of masculinising and feminising hormones for minors is expected to follow this consultation.
Verbatim Quotes
- “The NHS has exercised extreme caution when considering starting young people on this treatment.” — Professor James Palmer, National Medical Director for Specialised Services, NHS England
- “Banning new prescriptions of gender-affirming hormones for 16 and 17-year-olds is a profound attack on young people’s bodily autonomy with trans people yet again cruelly singled out by this government.” — Tammy Hymas, Policy Lead, TransActual
- “Under-18s are simply too young to consent to such irreversible, life-changing consequences,” — Helen Joyce, Director of Advocacy, Sex Matters
- “We will critically assess the NHS's evidence before responding, but given the gravity of these human rights concerns, we will consider legal action.” — TransLucent Statement
This pause in new referrals marks a significant shift in NHS England's approach to gender treatment for minors, reflecting ongoing debates about the balance between medical intervention and the rights of young individuals.
